GLP-1 receptor agonists tied to reduced kidney failure risk in bipolar disorder patients
Mayo Clinic researchers analyzed electronic health records and found that adults with bipolar disorder and chronic kidney disease who took GLP-1 receptor agonists were less likely to need dialysis or a kidney transplant. The study, published in the Journal of Clinical Psychiatry, suggests these diabetes and weight-loss medications may offer kidney protection for this high-risk group. The authors caution that prospective trials are needed to confirm whether the drugs directly slow kidney disease progression.
Mayo Clinic investigators examined de-identified records from TriNetX, an international network covering roughly 131 million adults at 117 health systems. They studied adults with bipolar disorder and mild-to-moderate chronic kidney disease who began GLP-1 receptor agonists or comparator drugs—DPP-4 inhibitors or RAAS inhibitors—using statistical matching and follow-up lasting as long as five years.
The link to fewer dialysis or transplant procedures appeared broadly similar across sex, race, obesity status, and psychiatric medication use, including lithium. Because the design was observational, the authors say prospective studies are needed to test whether GLP-1 drugs directly alter kidney disease progression. Published in Journal of Clinical Psychiatry.
If confirmed, this finding could matter to adults with bipolar disorder and chronic kidney disease, their families, and clinicians balancing psychiatric care with kidney protection. It may encourage closer coordination among psychiatry, nephrology, and primary care, and could eventually reduce dialysis or transplant needs. Because the evidence is observational, any societal benefit—such as less treatment burden or lower costs—remains uncertain until prospective trials clarify whether GLP-1 drugs directly slow kidney disease.